We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Cullinan Management Inc (CGEM) USD0.0001

Sell:$9.15 Buy:$18.83 Change: $0.69 (3.89%)
NASDAQ:0.12%
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:$9.15
Buy:$18.83
Change: $0.69 (3.89%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:$9.15
Buy:$18.83
Change: $0.69 (3.89%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cullinan Oncology, Inc. is a biopharmaceutical company. The Company is focused on creating standards of care for patients with cancer. The Company’s lead candidate, unpartnered program, CLN-619, is a monoclonal antibody designed to stabilize expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by both cytotoxic innate and adaptive immune cells. The Company is evaluating CLN-978, is a CD19xCD3 T cell engager with extended serum half-life and, based on preclinical data, robust potency against target cells expressing low levels of CD19. The Company's Zipalertinib (CLN-081/TAS6417), is an orally available small-molecule, irreversible epidermal growth factor receptor (EGFR) inhibitor that is designed to selectively target cells expressing EGFR exon 20 (EGFRex20) insertion mutations with relative sparing of cells expressing wild-type EGFR. The Company’s other product candidates include CLN-049, CLN-418, and CLN-617.

Contact details

Address:
One Main Street, Suite 1350
CAMBRIDGE
02142
United States
Telephone:
+1 (617) 4104650
Website:
https://www.cullinanoncology.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CGEM
ISIN:
US2300311063
Market cap:
$763.55 million
Shares in issue:
43.07 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Nadim Ahmed
    President, Chief Executive Officer, Director
  • Jeffrey Trigilio
    Chief Financial Officer, Treasurer
  • Jacquelyn Sumer
    Chief Legal and Compliance Officer, Company Secretary
  • Jeffrey Jones
    Chief Medical Officer
  • Jennifer Michaelson
    Chief Development Officer
  • Corinne Savill
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.